Cellular Logistics is developing a therapeutic targeted at various cardiac indications. EmVasc™ is delivered via intramuscular injection to diseased areas of the heart with a needle tip catheter to facilitate repair of damaged tissue following myocardial infarction or heart failure. Preliminary testing in small animals show significant improvement in heart function including improvements in cardiac contractility and a reversal in deleterious post myocardial infarction remodeling.
Extensive testing of EmVasc™ pro-regenerative biomaterial has demonstrated robust efficacy in multiple animal models. EmVasc™ reverses cardiac dilation (end systolic and diastolic volume) and increases cardiac contractility (End-systolic pressure volume relationship (ESPVR) in a rat myocardial infarction model.
In a mouse model of severe peripheral artery disease which results in inadequate blood flow to the affected limb, EmVasc™ and Cellogicus™ in combination with human mesenchymal stem cells significantly improved blood flow to the affected limb while reducing amputation and improving outcomes. This data demonstrates the ability of EmVasc™ and Cellogicus™ to improve outcomes in an additional model of ischemic disease.